drugset / Trial / NCT02022163
Safety, Tolerability and Immunogenicity of a Plant-made H7 Virus-like Particle (VLP) Influenza Vaccine in Adults.
Phase 1
Completed
100 enrolled
Medicago
Health Sciences Centre, Winnipeg, Manitoba · collabPublic Health Agency of Canada (PHAC) · collabSyneos Health · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
A phase I trial conducted in a single centre, observer-blind, randomized, dose-ranging, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of 2 intramuscular injections of plant-based H7 VLP Influenza Vaccine administered to healthy adults, 18-60 years of age.
Timeline
- Start
- 2013-12
- Primary completion
- 2014-09
- Completion
- 2014-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aluminum hydroxide | Unknown | — | Intramuscular |
| Subject | H7 VLP vaccine | Vaccine | — | Intramuscular |